Trial
NCT04960397
Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
—
Condition
H3N2 Influenza
Intervention
Placebo
Why stopped
Lack of product and funding.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-03